GH Research (GHRS) Total Liabilities (2021 - 2026)
GH Research (GHRS) posted quarterly Total Liabilities of $8.5 million for Q4 2025, down 8.53% year-over-year from $9.3 million in Q4 2024, and down 19.75% quarter-over-quarter from $10.6 million in Q3 2025.
GH Research (GHRS) Total Liabilities (2021 - 2026) Analysis & Trends
GH Research's Total Liabilities history runs 5 years deep, the most recent figure standing at $8.5 million for Q4 2025.
- In Q4 2025, Total Liabilities fell 8.53% year-over-year to $8.5 million; the TTM figure through Dec 2025 stood at $8.5 million (down 8.53% YoY), while the FY2025 annual figure was $8.5 million, down 8.53% from the prior year.
- Total Liabilities for Q4 2025 stood at $8.5 million, down from $10.6 million in the prior quarter.
- The five-year high for Total Liabilities was $10.6 million in Q3 2025, with the low at $2.0 million in Q3 2021.
- The 5-year median for Total Liabilities is $7.4 million (2023), against an average of $6.9 million.
- The sharpest annual moves came in 2023 and 2025: Total Liabilities jumped 135.51% in 2023, then declined 8.53% in 2025.
- GH Research's Total Liabilities stood at $3.4 million in 2021, then soared by 34.42% to $4.5 million in 2022, then soared by 61.28% to $7.3 million in 2023, then advanced by 27.14% to $9.3 million in 2024, then retreated by 8.53% to $8.5 million in 2025.
- Business Quant data shows GHRS's Total Liabilities at $8.5 million in Q4 2025, $10.6 million in Q3 2025, and $10.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | GH Research | 2.02 Bn | 1.68 Bn | - | 12.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.86 Mn |
| Dec 31, 2025 | 8.53 Mn |
| Sep 30, 2025 | 10.63 Mn |
| Jun 30, 2025 | 10.25 Mn |
| Mar 31, 2025 | 10.24 Mn |
| Dec 31, 2024 | 9.32 Mn |
| Sep 30, 2024 | 10.25 Mn |
| Jun 30, 2024 | 8.30 Mn |
| Mar 31, 2024 | 7.84 Mn |
| Dec 31, 2023 | 7.33 Mn |
| Sep 30, 2023 | 6.80 Mn |
| Jun 30, 2023 | 7.29 Mn |
| Mar 31, 2023 | 7.43 Mn |
| Dec 31, 2022 | 4.55 Mn |
| Sep 30, 2022 | 3.39 Mn |
| Jun 30, 2022 | 3.10 Mn |
| Mar 31, 2022 | 4.07 Mn |
| Dec 31, 2021 | 3.38 Mn |
| Sep 30, 2021 | 2.03 Mn |